Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate.
Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 years
NVX-CoV2373 was generally well-tolerated and had a reassuring safety profile
The vaccine induced neutralization titers in 100% of participants
Both 5 µg and 25 µg adjuvanted doses generated peak geometric mean titer (GMT) greater than 1:3,300
Matrix-M™ adjuvant induced robust polyfunctional CD4+ T cell responses
See our AmpCard for details.